Cercosporamide | Mnk inhibitor

Cercosporamide chemical structure

Available Options

Size:PriceQuantity 
200 µg$90.00
1 mg$370.00
Request Quote / Bulk / Custom Size
Product Inquiry

Cercosporamide (131436-22-1) is a natural product isolated from Cercosporidium henningsii and shown to have antifungal activity.1 It was found to be a potent inhibitor of MAP kinase interacting kinase (Mnk1 IC50=116 nM and Mnk2  IC50=11 nM), with selectivity against a panel of 76 kinases (at 20 µM) with the exception of JAK3 (IC50=31 nM).2 It effectively blocks eIF4E phosphorylation both in vitro and in vivo and induces apoptosis in multiple cancer cell lines.2 It enhances the response to antiangiogenic drugs in renal cell carcinoma3 and overcomes chemoresistance in cervical cancer4.

References/Citations:

  1. Sugawara et al. (1991), The structure and biological activity of cercosporamide from Cercosporidium henningsii; J. Org. Chem., 56 909
  2. Koniceki et al. (2011), Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases; Cancer Res., 71 1849
  3. Chen et al. (2020), Preclinical evidence that MNK/eIF4E inhibition by cercosporamide enhances the response to antiangiogenic TKI and mTOR inhibitor in renal cell carcinoma; Biochem. Biophys. Res. Commun., 530 142
  4. Zhu et al. (2021), Targeting of MNK/eIF4E overcomes chemoresistance in cervical cancer; J. Pharm. Pharmacol., 73 1418
131436-22-1, Cercosporamide, Cercosporamide supplier, MNK inhibitor

Safety Data Sheet:

N/A

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

Cercosporamide (131436-22-1) is a natural product isolated from Cercosporidium henningsii and shown to have antifungal activity.1 It was found to be a potent inhibitor of MAP kinase interacting kinase (Mnk1 IC50=116 nM and Mnk2  IC50=11 nM), with selectivity against a panel of 76 kinases (at 20 µM) with the exception of JAK3 (IC50=31 nM).2 It effectively blocks eIF4E phosphorylation both in vitro and in vivo and induces apoptosis in multiple cancer cell lines.2 It enhances the response to antiangiogenic drugs in renal cell carcinoma3 and overcomes chemoresistance in cervical cancer4.

References/Citations:

  1. Sugawara et al. (1991), The structure and biological activity of cercosporamide from Cercosporidium henningsii; J. Org. Chem., 56 909
  2. Koniceki et al. (2011), Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases; Cancer Res., 71 1849
  3. Chen et al. (2020), Preclinical evidence that MNK/eIF4E inhibition by cercosporamide enhances the response to antiangiogenic TKI and mTOR inhibitor in renal cell carcinoma; Biochem. Biophys. Res. Commun., 530 142
  4. Zhu et al. (2021), Targeting of MNK/eIF4E overcomes chemoresistance in cervical cancer; J. Pharm. Pharmacol., 73 1418